Plus   Neg

Novartis Pharma Announces Simultaneous Approval Of Five New Products In Japan

Novartis Pharma K.K. announced that Japanese Ministry of Health, Labour and Welfare has issued simultaneous approval for the company's five new products. Tabrecta, an oral MET inhibitor for MET exon 14 skipping mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer, was approved. The other approved products are: Entresto in chronic heart failure, Mayzent in secondary progressive MS, Enerzair and
Atectura in different forms of asthma.

Kazunari Tsunaba, Representative Director and President of Novartis Pharma, said: "All five medicines are truly novel and transformative treatments and therefore mark an important milestone in our mission to reimagine medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Polaris Industries Inc. is recalling certain Ranger and General Utility, as well as All-Terrain vehicles citing risks of crash, the U.S. Consumer Product Safety Commission said in a statement. The Medina, Minnesota-based company has called back about 26,730 units of Model Year 2019 - 2020 Ranger XP 1000 & Model Year 2020 General XP 1000 Utility vehicles. Gilead Sciences Inc. (GILD) said Friday that the European Commission has granted conditional marketing authorization for Veklury or remdesivir as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19. FedEx is asking NFL team Washington Redskins to change its name for its racist connotations. The delivery services company, which is a major sponsor for the team, made the suggestion following increasing pressure from its investors amid the ongoing protests against racial injustice and inequality that arose from the killing of African-American George Floyd.
Follow RTT